BMS-936559

BMS-936559 è un anticorpo completamente umano della classe delle immunoglobuline G4 (IgG4), diretto su PD-L1; è stato testato in 55 pazienti con melanoma metastatico, che costituivano una parte di tutti coloro che sono stati sottoposti ad uno studio di fase I [Brahmer, et al, 2012]. Il 56% dei pazienti era stato trattato, in precedenza, con immunoterapia e il 9% aveva ricevuto, in passato, la terapia con gli inibitori di BRAF. Le infusioni di BMS-936559 sono state eseguite ogni 2 settimane. Il tasso di risposta globale è stato pari al 17% ed è variato tra il 6% e il 29% all’interno dell’intervallo di dosaggio pari a 0,3-10 mg/kg. In particolar modo, il tasso di risposta più elevato è stato osservato alla dose di 3 mg/kg. Il 27% dei pazienti, trattati con l’anticorpo in esame, ha presentato la malattia stabile per oltre 6 mesi. Le tossicità sono state generalmente lievi e gestibili. All’interno del gruppo totale di pazienti esaminati, il 9% ha manifestato tossicità di grado 3 e il 39% ha avuto reazioni avverse immunitarie di qualsiasi grado, che hanno incluso rash, ipotiroidismo, epatite, sarcoidosi, endoftalmite, diabete mellito e miastenia grave.

BIBLIOGRAFIA

 AA VV. Tremelimumab. Drugs R D. 10:123-132. 2010.

 Acharya U H, Jeter J M. Use of ipilimumab in the treatment of melanoma. Clinical Pharmacology: Advances and Applications. 5:21-27. 2013.

 Ackerman A, McDermott D F, Lawrence D P, et al. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. J Clin Oncol. 30:abstr 8569. 2012.

 Aggarwal S, Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105:1815-1822. 2005.

 Ahmad S, Lewis M, Corrie P, et al. Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract. 18:287-292. 2012.

 Akhtari M, Waller E K, Jaye D L, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 32:322-324. 2009.

 Almeida V L, Leita͂o A, Reina Barrett L C, Montanari C A, Donnici C L, Lopes M T P. Ca͂ncer e agentes antineoplásicos ciclo-celular específicos e ciclo-celular na͂o específicos que interagem com o DNA: uma introduça͂o. Quim Nova. 28:118-129. 2005.

 Andrews S, Holden R. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res. 4:299-307. 2012.

 Anonymous [Study No. DS06064; BMS-663513 and BMS-734016 (MDX-010)]: One-month Intravenous Combination Toxicity Study in Monkeys. Bristol-Myers Squibb Company. 2007.  Ascierto P A, Simeone E, Giannarelli D, et al. Sequencing of BRAF inhibitors and ipilimumab

in patients with metastatic melanoma: A possible algorithm for clinical use. J Transl Med. 10:107. 2012.

 Ascierto P, Marincola F, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med. 9:196. 2011.

 Atkins M B, Hsu J, Lee S, Cohen G I, Flaherty L E, Sosman J A, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin- 2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 26:5748-5754. 2008.

 Atkins M B, Lotze M T, Dutcher J P, Fisher R I, Weiss G, Margolin K, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 17:2105-2116. 1999.

 Attia P, Phan G Q, Maker A V, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen -4. J Clin Oncol. 23:6043-6053. 2005.

 Avril M F, Aamdal S, Grob J J, Hauschild A, Mohr P, Bonerandi J J, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba J L, Scherrer A, Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol. 22:1118-1125. 2004.

 Balch C M, Gershenwald J E, Soong S J, Thompson Atkins M B, Byrd D R, Buzaid A C, Cochran A J, Coit D G, Ding S, Eggermont A M, Flaherty K T,Gimotty P A, Kirkwood J M, McMasters K M, Mihm M C Jr, Morton D L, Ross M I, Sober A J, Sondak V K. Final version of 2009 AJCC melanoma staging and classification . J Clin Oncol. 27:527-534. 2009.  Balch C M, Soong S J, Murad T M, Smith J W, Maddox W A, Durant J R. A multifactorial

analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant matastases (stage III). J Clin Oncol. 1:126-134. 1983.

 Barnard Z R, Walcott B P, Kahle K T, et al. Hyponatremia associated with ipilimumab- induced hypophysitis. Med Oncol. 29:374-377. 2012.

 Barth A, Wanek L A, Morton D L. Prognostic factors in 1521 melanoma patients with distant meastases. J Am Coll Surg. 181:193-201. 1995.

 Bárzaga H O V. Caracterización clinica e histopatológica del cáncer cutáneo no melanoma. Arch Méd Camaguey. 14:0-. 2010.

 Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 113:1581-1588. 2009.

 Beck K E, Blansfield J A, Tran K Q, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 24:2283-2289. 2006.  Bedane C, Leccia M T, Sassolas B, Bregman B, Lebbé C. French investigators of the

MELODY study: Treatment patterns and outcomes in patients with advanced melanoma in France. Curr Med Res Opin. 29:1297-1305. 2013.

 Bentzen S M, Thames H D. Tumor volume and local control probability: Clinical data and radiobiological interpretations. Int J Rad Oncol Biol Phys. 36:247-251. 1996.

 Bergman P J, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogenic human tyrosinase: a phase I trial. Clin Cancer Res. 9:1284-1290. 2003.

 Berman D, Parker S M, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immunol. 10:11. 2010.

 Boni A, Cogdill A P, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70:5213-5219. 2010.

 Boon T, Coulie P G, Van den Eynde B J, Van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 24:175-208. 2006.

 Borodic G, Hinkle D M, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plastic and Reconstructive Surgery. 27:e87-e88. 2011.

 Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455-2465. 2012.  Brocker T, Gulbranson-Judge A, Flynn S, Riedinger M, Raykundalia C, Lane P. CD4 T cell

traffic control: in vivo evidence that ligation of OX-40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol. 29:1610-1616. 1999.

 Callahan M K, Wolchok J D, Allison J P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 37:473-484. 2010.  Camacho L H, Antonia S, Sosman J, Kirkwood J M, Gajewski T F, Redman B, Pavlov D,

Bulanhagui C, Bozon V A, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 27:1075-1081. 2009.

 Carpenter K J, Murtagh R D, Lilienfeld H, Weber J, Murtagh F R. Ipilimumab-induced hypophysitis: MR imaging findings. The American Journal of Neuroradiology. 30:1751-1753. 2009.

 Carthon B, Wolchok J, Yuan J, et al. Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 16:2861- 2871. 2010.

 Carvajal R D, Antonescu C R, Wolchok J D, Chapman P B, Roman R A, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 305:2327-2334. 2011.

 Cecchinato V, Tryniszewska E, Ma Z M, Vaccari M, Boasso A, Tsai W P, et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol. 180:5439-5447. 2008.

 Chambers C A, Sullivan T J, Allison J P. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 7:885-895. 1997.  Chapman P B, Hauschild A, Robert C, Haanen J B, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507-2516. 2011.

 Cheng S, Koch W H, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol. 29:682-688. 2012.

 Chmiel K D, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 29:e237-e240. 2011.

 Curiel T J, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10:942-949. 2004.

 Curran M A, Montalvo W, Yagita H, Allison J P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 107:4275-4280. 2010.

 Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 61:41-48. 2012.

 Das Thakur M, Salangsang F, Landman A S, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494:251-255. 2013.

 Davies H, Bignell G R, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett M J, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson B A, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins G J, Bigner D D, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho J W, Leung S Y, Yuen S T, Weber B L, Seigler H F, Darrow T L, Paterson H, Marais R, Marshall C J, Wooster R, Stratton M R, Futreal P A. Mutations of the BRAF gene in human cancer. Nature. 417:949-954. 2002.

 Davis I D, Brady B, Kefford R F, Millward M, Cebon J, Skrumsager B K, et al. Clinical and biological efficacy of recombinant human interleukin-2 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 15:2123-2129. 2009.

 Delfino G, Lanciotti E, Liguri G, Stefani M. Medicina e Biologia – Medicine & Biology. 2012. Zanichelli Editore.

 Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. The New England Journal of Medicine. 365:1747-1748. 2011.

 Di Giacomo A M, Biagioli M, Maio M. The emerging toxicity profiles of antiCTLA-4 antibodies across clinical indications. Seminars in Oncology. 37:499-507. 2010.

 Di Giacomo A M, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13:879-886. 2012.

 Dillard T, Yedinak C G, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 13:29-38. 2010.

 Drake C. Radiation-induced immune. Molecular determinants of radiation response. 251-263. 2011.

 Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R C. Vaccination with irradiated tumor cells engineered to secrete GM- CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA. 90:3539-3543. 1993.

 Druker B J, Sawyers C L, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia with the Philadelphia chromosome. N Engl J Med. 344:1038-1042. 2001.

 Dudley M E, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854. 2002.

 Duffy K, Grossman D. The dysplastic naevus: from historical perspective to management in the modern era part I. Historical, histologic, and clinical aspects. Journal of the American Academy of Dermatology. 67:1-e-16. quiz 7-8. 2012.

 Dummer R, Maio M, Hamid O, et al. Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. Proceedings of the 14th Perspectives in Melanoma. Abstract P-0004. 2010.

 Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 218:69-70. 2009.

 Egberts F, Pollex A, Egberts J H, Kaehler K C, Weichenthal M, Hauschild A. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker

 Eggermont A M. Advances in systemic treatment of melanoma. Ann Oncol. 21:vii 339-344. 2010.

 Eggermont A M, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer. 47:2150-2157. 2011.

 Eggermont A M, Suciu S, Santinami M, Testori A, Kruit W H, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTIC 18991, a randomised phase III trial. Lancet. 372:117- 126. 2008.

 Elder D E. Dysplastic naevi:an update. Histopatology. 56:112-120. 2010.

 EMA. Yervoy. Available at

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002213/hu man_med_001465.jsp&mid=WC0b01ac058001d124 2013.

 EMA. Yervoy (Ipilimumab). Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_repor t/human/002213/WC500109302.pdf 2011.

 Facciabene A, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 475:226-230. 2011.

 Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 361:211-212. 2009.

 FDA. Yervoy (Ipilimumab) Pharmacology Review. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125377Orig1s000PharmR.pdf 2011.

 Fecci P E, Ochiai H, Mitchell D A, Grossi P M, Sweeney A E, Archer G E, Cummings T, Allison J P, Bigner D D, Sampson J H. Systemic CTLA-4 blockade ameliorates glioma- induced changes to the CD4+ T cell compartment without affecting regulatory T cell function. Clin Cancer Res. 13:2158-2167. 2007.

 Fecher L A, Agarwala S S, Hodi F S, Weber J S. Ipilimumab and Its Toxicities: A Multidisciplinary Approach. The Oncologist. 18:733-743. 2013.

 Feng Y, Masson E, Dai D, Parker S M, Barman D, Roy A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 78:106-117. 2014.

 Flaherty K T, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov L V, Hassel J C, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin J M, Utikal J, Dreno B, Nyakas M, Middleton M R, Becker J C, Casey M, Sherman L J, Wu F S, Ouellet D, Martin A M, Patel K,

Schadendorf D, METRIC Study Group. Improved survival with MEK inhibition in BRAF- mutated melanoma. N Engl J Med. 367:107-114. 2012.

 Forschner A, Heinrich V, Pflugfelder A, Meier F, Garbe C. The role of radiotherapy in the overall treatment of melanoma. Clin Dermatol. 31:282-289. 2013.

 Freeman G J, Gribben J G, Boussiotis V A, Ng J W, Restivo V A, Lombard L A, Gray G S, Nadler L M. Cloning of B7-2: a CTLA-4 counter-receptor that co-stimulates human T cell proliferation. Science. 262:909-911. 1993.

 Frosch P J, Czarnetzki B M, Macher E, et al. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J Cancer Res Clin Oncol. 95:281-286. 1979.  Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma.

Prog Biophys Mol Biol. 107:362-366. 2011.

 Gandini S, Sera F, Cattaruzza M S, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 41:28-44. 2005.

 Geller A G, Clapp R W, Sober A J, Gonsalves L, Mueller L, Christiansen C L, Shaikh W, Miller D R. Melanoma epidemic: An analysis of six decades of Data From the Connecticut Tumor Registry. J Clin Oncol. 31:4172-4178. 2013.

 Goldstein A M, Tucker M A. Genetic epidemiology of cutaneous melanoma: a global perspective. Archives of dermatology. 137:1493-1496. 2001.

 Gordon I O, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 58:1351-1353. 2009.  Gramaglia I, Weinberg A D, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory

molecule for sustaining primary CD4 T cell responses. J Immunol. 161:6510-6517. 1998.  Gregor P D, Wolchok J D, Ferrone C R, et al. CTLA-4 blockade in combination with

xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 22:1700-1708. 2004.

 Grosso J F, Jure-Kunkel M N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunità. 13:1-14. 2013.

 Hahn E A, Glendenning G A, Soresen M V, et al; IRIS Investigators. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 21:2138- 2146. 2003.

 Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams D M, Gómez H, Bastholt L, Chasalow S D, Berman D. A prospective phase II trial exploring the

association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 9:204-219. 2011.

 Hamnvik O P, Larsen P R, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 103:1572-1587. 2012.

 Harrell F E Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer, 2010.

 Hauschild A, Grob J J, Demidov L V, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank C U, Miller W H Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion- Sileni V, Martin A M, Swann S, Haney P, Mirakhur B, Guckert M E, Goodman V, Chapman P B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase III randomised controlled trial. Lancet. 380:358-365. 2012.

 Hodi F S, Mihm M C, Soiffer R J, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 100:4712-4717. 2003.

 Hodi F S, O’Day S J, McDermott D F, Weber R W, Sosman J A, Haanen J B, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711-723. 2010.

 Hoos A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 37:533-546. 2010.

 Huang C T, et al. Role of LAG-3 in regulatory T cells. Immunity. 21:503-513. 2004.

 Hurtado J C, Kim S H, Pollok K E, Lee Z H, Kwon B S. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol. 155:3360-3367. 1995.

 Hutloff A, Dittrich A M, Beier K C, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek R A. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 397:263-266. 1999.

 Iannone R, Gergich K, Cong C, Kang P, Daud A, Dronca R, et al. Efficacy and safety of MK- 3475 in patients with advanced melanoma. Pigment Cell Melanoma Res. 25:864-865. 2012.  Ibrahim R, Berman D, De Pril V, et al. Ipilimumab safety profile: summary of findings from

completed trials in advanced melanoma. Journal of Clinical Oncology. 29:abstract no.8583. 2011.

 Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman R M. Generation of large numbers of dendritic cells from mouse bone marrow cultures

supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 176:1693- 1702. 1992.

 June C H. Principles of adoptive T cell cancer therapy. J Clin Invest. 117:1204-1212. 2007.  Jungbluth A A, Chen Y T, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1

antigen expression in normal and malignant human tissues. Int J Cancer. 92:856-860. 2001.  Kaleeba J A, Offner H, Vandenbark A A, Lublinski A, Weinberg A D. The OX-40 receptor

provides a potent co-stimulatory signal capable of inducine encephalitogenicity in myelin- specific CD4+ T cells. Int Immunol. 10:453-461. 1998.

 Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can estabilish memory in patients with advanced leukemia. Sci Transl Med. 3:95ra73. 2011.  Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with

vaccines in cynomolgus macaques. J Immunol. 171:6521-6529. 2003.

 Khayat D, Bernard-Marty C, Meric J B, Rixe O. Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol. 20:2411-2414. 2002.

 Kingsley D P. An intersting case of possible abscopal effect in malignant melanoma. Br J Radiol. 48:863-866. 1975.

 Kirkwood J M, Ibrahim J G, Sondak V K, Richards J, Flaherty L E, Ernstoff M S, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 18:2444-2458. 2000.

 Kohn D B, Dotti G, Brentjens R, et al. CARs on track in the clinic. Mol Ther. 19:432-438. 2011.

 Kooi S, et al. HLA class I expression on human ovarian carcinoma cells correlates with T- cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol. 174:116-128. 1996.

 Krummel M F, Allison J P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 183:2533-2540. 1996.

 Ku G Y, Yuan J, Page D B, Schroeder S E, Panageas K S, Carvajal R D, Chapman P B, Schwartz G K, Allison J P, Wolchok J D. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 116:1767-1775. 2010.

 Lacouture M E, Melosky B L. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Letter. 12:1-5. 2007.

 Lane P. Regulation of T and B Cell Responses by Modulating Interactions between CD28/CTLA-4 and Their Ligands, CD80 and CD86. Ann NY Accad Sci. 392-400. 1997.  Lane P. Role of OX-40 signals in coordinating CD4 T cell selection, migration, and cytokine

differentiation in T helper (Th)1 and Th2 cells. J Exp Med. 191:201-206. 2000.

 Leach D R, Krummel M F, Allison J P. Enhancement of anti-tumor immunity by CTLA-4 blockade. Science. 271:1734-1736. 1996.

 Lebbé C, et al. Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials. Ann Oncol. 23:(suppl 9), abstract 1116PD. 2012.

 Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 5:3. 2012.

 Lemech C, Arkenau H T. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol. 6:53-66. 2012.

 Lenschow D J, Su G H, Zuckerman L A, Nabavi N, Jellis C L, Gray G S, Miller J, Bluestone J A. Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA. 90:11054-11058. 1993.

 Levitsky H I, Lazenby A, Hayashi R J, Pardoll D M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 179:1215-1224. 1994.  Linsley P S, Greene J L, Brady W, Bajorath J, Ledbetter J A, Peach R. Human B7-1 (CD80)

and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1:793-801. 1994.

 Luke J J, Hodi F S. Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. The Oncologist. 18:717-725. 2013.

 Maker A V, Phan G Q, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 12:1005-1016. 2005.

 Margolin K, et al. Ipilimumab in patients with melanoma and brain metastases. Lancet Oncol. 13:459-465. 2012.

 Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 222:162-179. 2008.  Marx J, Hockberger R, Walls R. Rosen’s Emergency Medicine, 7th ed. Philadelphia, P A:

 Mauro M J, Druker B J. STI571: a gene product-targeted therapy for leukemia. Curr Oncol Rep. 3:223-227. 2001.

 McLellan A D, Starling G C, Williams L A, Hock B D, Hart D N. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecole. Eur J Immunol. 25:2064-2068. 1995.

 Melero I, Shuford W W, Newby S A, Aruffo A, Ledbetter J A, Hellstrom K E, Mittler R S, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 3:682-685. 1997.

 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 480:480- 489. 2011.

 Mellman I, Steinman R M. Dendritic cells:specialized and regulated antigen processing machines. Cell. 106:255-258. 2001.

 Mellor A L, Munn D H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev Immunol. 4:762-774. 2004.

 Menzies A M, Long G V. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol. 5:278-285. 2013.

 Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol. 23:5088-5093. 2005.

 Miliotes G, Lyman G H, Cruse C W, Puleo C, Albertini P A, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol. 3:558-563. 1996.

 Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma is associated with secondary adrenal insufficiency: A case series. Endocr Pract. 18:351-355. 2012.

 Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 164:303-307. 2011.

 Mole R H. Whole body irradiation: radiobiology or medicine? Br J Radiol. 26:234-241. 1953.

 Mosavi F, Ullenhag G, Ahlström H. Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma. Ups J Med Sci. 118:91-97. 2013.

 National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0.

 Neller M A, Lopez J A, Schmidt C W. Antigens for cancer immunotherapy. Semin Immunol.

Nel documento NUOVI ORIZZONTI NEL TRATTAMENTO DEL MELANOMA CUTANEO: IPILIMUMAB E FARMACI IMMUNOTERAPICI DI ULTIMA GENERAZIONE (pagine 66-83)